✦ LIBER ✦

Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia

✍ Scribed by Yanmin Zhao; Yamin Tan; Gongqiang Wu; Lizhen Liu; Yingjia Wang; Yi Luo; Jimin Shi; He Huang

Book ID: 107619331
Publisher: Carden Jennings Publishing
Year: 2011
Tongue: English
Weight: 216 KB
Volume: 94
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-011-0887-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Granulocyte–colony-stimulating factor (f

Granulocyte–colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

✍ Alfonso Quintas-Cardama; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Maner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract ## BACKGROUND Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade ≥ 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in

EUTOS score predicts survival and cytoge

EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

✍ Tao, Zhongfei; Liu, Bingcheng; Zhao, Yaozhong; Wang, Ying; Zhang, Rongli; Han, M 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Granulocyte—colony-stimulating factor (F

Granulocyte—colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

✍ Heather G. Jørgensen; Mhairi Copland; Tessa L. Holyoake 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Late response to low-dose imatinib in pa

Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia

✍ Akiyoshi Takami, Shigeki Ohtake, Eriko Morishita… 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 230 KB

Dasatinib induces significant hematologi

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

✍ Guilhot, F.; Apperley, J.; Kim, D.-W.; Bullorsky, E. O.; Baccarani, M.; Roboz, G 📂 Article 📅 2007 🏛 American Society of Hematology 🌐 English ⚖ 137 KB

Correlation Between Imatinib Pharmacokin

Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia

✍ Takahashi, N; Wakita, H; Miura, M; Scott, S A; Nishii, K; Masuko, M; Sakai, M; M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 148 KB